Why did this ASX biotech stock explode 36% today?

This ASX nano-cap healthcare share has leapt 47% in just a week.

| More on:
Scientist looking at a laptop thinking about the share price performance.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX biotech stock PainChek Ltd (ASX: PCK) rocketed 36% higher this afternoon, prompting the ASX to issue a price query.

The Painchek share price hit a new 52-week high of 4.6 cents today. It has since slipped back to 4.3 cents at the close of trade.

The biotech stock's upward bolt today followed the same trajectory as two other micro-cap healthcare shares that charged higher this morning after releasing news updates.

ASX asks biotech to 'please explain' share price skyrocket

In its price query, the ASX referred to PainCheck's ascension from a closing price of 2.9 cents on 19 September to 4.5 cents at the time.

It also noted a "significant increase in the volume of PCK's securities traded on 20 September 2023 and today".

The ASX biotech responded by saying it knew of no reason for the stock's rapid rise.

The company confirmed it had no undisclosed news to declare.

Painchek said it was "possible that the market may be reacting to the recent issue of shares as part of the placement that was announced on 14 September 2023".

$3.55 million placement to fund product development

The ASX biotech stock has leapt 47% since announcing a successful $3.55 million capital raise among institutional, professional and sophisticated investors last Thursday.

Painchek will use the funding to continue developing its smartphone-based medical device application.

The company has an app called Painchek Universal, which allows patients who cannot self-report their level of pain to communicate this to their carers.

The app uses artificial intelligence and facial recognition to detect pain levels.

The company said it will use the placement funds for the following key purposes:

  • Continue the international commercialisation of the Adult App in aged care and for the hospital and homecare sector
  • Submit Adult App US FDA De Novo regulatory clearance application for US market entry with
  • established US partners
  • Commence commercialisation of the Infant App, including novel vocalisation technology
  • Complete a core technology upgrade and obtain ISO27001 certification

The ASX biotech company issued an investor presentation for stockholders on 14 September.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientists working in the laboratory and examining results.
Healthcare Shares

Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares

Canaccord Genuity recommends a 'basket approach' when investing in these types of stocks.

Read more »

A worried woman looks at her phone and laptop, seeking ways to tighten her belt against inflation.
Healthcare Shares

This ASX share potentially 'has no value from here', says broker

This is every investor's worst nightmare.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Healthcare Shares

Should I buy Fisher & Paykel or ResMed shares?

Let's see which of these two names could be best buys.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This company has entered a trading halt, is it about to announce FDA approval?

This regenerative medicine company is up more than 260% in the last year.

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

How are Cochlear shares impacted by Trump's tariffs?

Will the company escape from the tariffs? Let's find out.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

3 reasons to buy this surging ASX All Ords healthcare share today

A top expert forecasts more outperformance from this rocketing ASX healthcare stock.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Down 11% in 2025, are CSL shares a good buy right now?

Are CSL shares likely to go up from here?

Read more »

Three healthcare workers look and point at at medical image
Healthcare Shares

Pro Medicus to buyback 10.4 million shares. What does this mean?

Is this a sign to buy?

Read more »